Irbesartan + Hidroclorotiazida Stada

Irbesartan, the active ingredient in Irbesartan + Hidroclorotiazida Stada, is an angiotensin II receptor blocker presented as a tablet for oral use. It lowers blood pressure in adults with hypertension and is indicated for the treatment of essential hypertension, often in combination with a thiazide diuretic.

GNH USA supplies Irbesartan + Hidroclorotiazida Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is indicated for the management of hypertension, a condition characterized by elevated arterial pressure. - Essential hypertension: reduces systolic and diastolic blood pressure in adults. - Hypertension with fluid retention: improves control by combining vasodilation and diuretic action. - High‑risk cardiovascular patients: contributes to lowering cardiovascular risk when used as part of a comprehensive treatment plan.

The combination may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Mild electrolyte disturbances (e.g., low potassium) - Gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration - Acute kidney injury - Hyperkalemia - Angioedema - Marked hypotension - Blood dyscrasias (e.g., agranulocytosis)

Before initiating therapy, several precautions should be considered to ensure safe use. - Renal function: assess kidney function and adjust dose if impairment is present. - Electrolyte balance: monitor serum potassium and sodium regularly during treatment. - Volume status: evaluate for dehydration or fluid overload before and during therapy. - Concomitant antihypertensives: adjust dosing to avoid excessive blood pressure reduction. - Pregnancy: avoid use unless clearly needed; discuss potential risks with a healthcare professional. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Irbesartan/HCTZ can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors or ARBs combined with NSAIDs: increased risk of renal impairment. - Lithium: concomitant use may raise lithium concentrations. - Cyclosporine: may enhance nephrotoxic effects. - Strong CYP3A4 inhibitors (e.g., itraconazole): increase irbesartan levels.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): additive blood pressure lowering. - NSAIDs: may reduce diuretic effectiveness. - Digoxin: possible alteration of serum levels. - Additional thiazide diuretics: increased electrolyte disturbances. - Antidiabetic agents: may require dose adjustment due to blood pressure changes.